Foghorn Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Foghorn Therapeutics, Inc. - overview
Established
2016
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2016 and led by CEO Adrian Gottschalk, Foghorn Therapeutics, Inc. operates as a pharmaceutical research and development company providing therapies for the treatment of cancer and other serious diseases using their Gene Traffic Control platform. As of 2024, the company is listed in Nasdaq with ticker symbol FHTX. In May 2024, Foghorn Therapeutics, Inc.
raised USD 110 million in PIPE funding from BVF Partners and Deerfield Management, with participation from Flagship Pioneering. Foghorn Therapeutics, Inc. developed a gene traffic control platform, which is an integrated, mechanistic understanding of chromatin regulatory system components to systematically identify, validate, and target potential drug candidates. The company’s therapeutic candidates are designed to remodel DNA's shape, tackling diseases associated with chromatin regulatory system breakdowns.
In addition, the firm focuses on correcting abnormal gene expression in oncology. The company plans to use the funding from May 2024 to advance our programs through multiple data readouts and clinical value inflection points as we continue to develop medicines for patients.
Current Investors
Flagship Pioneering
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.foghorntx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Foghorn Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Foghorn Therapeutics, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.